HRGN
What one share of Harvard Apparatus Regenerative Technology holds
Surgical and Medical Instruments and Apparatus
We are a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastro-intestinal system and other organs that result from cancer, trauma or birth defects.
Harvard Apparatus Regenerative Technology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.06 |
|---|---|
| Profit | −$0.39 |
| Cash and investments | $0.02 |
| Book value | −$0.08 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.10 | −$14.49 | $0.38 | −$11.71 | — | $2.07 |
| 2017 | $0.00 | −$6.63 | $0.08 | −$6.20 | — | $1.37 |
| 2018 | $0.00 | −$1.69 | $0.03 | −$1.74 | — | $0.35 |
| 2019 | $0.00 | −$1.21 | $0.02 | −$0.90 | — | $0.13 |
| 2020 | $0.00 | −$0.55 | $0.00 | −$0.46 | — | $0.12 |
| 2021 | $0.00 | −$0.79 | $0.00 | −$0.26 | — | −$0.28 |
| 2022 | — | −$0.55 | $0.00 | −$0.45 | — | −$0.26 |
| 2023 | $0.01 | −$0.67 | $0.00 | −$0.52 | — | $0.12 |
| 2024 | $0.03 | −$0.52 | $0.00 | −$0.33 | — | $0.20 |
| 2025 | $0.04 | −$0.42 | — | −$0.23 | — | $0.06 |